Микросателлитная нестабильность при раке эндометрия: место методов определения и их клиническое применение. Согласованное мнение экспертов

Дефицит системы репарации неспаренных оснований представляет собой уникальное молекулярное нарушение, встречающееся в 20-30 % опухолей эндометрия. Исследование дефицита системы репарации неспаренных оснований/наличия микросателлитной нестабильности приносит диагностическую пользу, поскольку эти нарушения являются биомаркером эндометриальной аденокарциномы, повышает возможности идентификации пациенток группы высокого риска развития синдрома линча, определяет прогноз жизни пациентки и дает понимание эффективности ингибиторов контрольных точек и их комбинаций. В настоящей обзорной статье представлены современные данные по диагностике, прогностической и предиктивной значимости микросателлитной нестабильности при раке эндометрия, а также предполагаемый алгоритм тестирования дефицита системы репарации/микросателлитной нестабильности.

1. Состояние онкологической помощи населению России в 2021 г. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.

2. Statistics Adapted from the American Cancer Society's (ACS) Publication, Cancer Facts & Figures 2022, the ACS Website, and the International Agency for Research on Cancer Website. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html.

3. Travaglino A., Raffone A., Mascolo M. et al. Clear cell endometrial carcinoma and the TCGA classification. Histopathology 2020;76:336-68. DOI: 10.1111/his.13976

4. The Cancer Genome Atlas Research Network. Levine D. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73. DOI: 10.1038/nature12325

5. Hewish M., Lord C.J., Martin S.A. et al. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 2010;7(4):197-208.

6. Sinicrope F.A. Lynch syndrome-associated colorectal cancer. N Engl J Med 2018;379(8):764-73.

7. Woods M.O., Williams P., Careen A. et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 2007;28(7):669-73.

8. Mensenkamp A.R., Vogelaar I.P., van Zelst-Stams W.A. et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014;146(3):643-646.e8.

9. Antelo M., Golubicki M., Roca E. et al. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer. Int J Cancer 2019;145(3):705-13.

10. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138(6):2073-2087.e2073.

11. Hernandez J.S. Cost-effectiveness of laboratory testing. Arch Pathol Lab Med 2003;127(4):440-5. DOI: 10.5858/2003-127-0440-COLT

12. Stinton C., Fraser H., Al-Khudairy L. et al. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies: A systematic review of test accuracy. Gynecol Oncol 2021;160:148-60.

13. Concin N., Matias-Guiu X., Vergote I. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31(1):12-39. DOI: 10.1136/ijgc-2020-002230

14. Makker V., Colombo N., Casado Herraez A. et al. lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. DOI: 10.1056/NEJMoa2108330

15. O'Malley D.M., Bariani G.M., Cassier P.A. et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022;40(7):752-61. DOI: 10.1200/JCO.21.01874

16. Malapelle U., Parente P., Pepe F. et al. Evaluation of microsatellite instability and mismatch repair status in different solid tumors: a multicenter analysis in a real world setting. Cells 2021;10:1878.

17. Kurnit K.C., Westin S.N., Coleman R.L. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer 2019;125(13):2154-63. DOI: 10.1002/cncr.32058

18. Alpert L., Pai R.K., Srivastava A. et al. Colorectal carcinomas with isolated loss of PMS2 staining by immunohistochemistry. Arch Pathol Lab Med 2018;142(4):523-8.

19. Pearlman R., Markow M., Knight D. et al. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Mod Pathol 2018;31(12):1891-900.

20. Graham R.P., Kerr S.E., Butz M.L. et al. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas. Am J Surg Pathol 2015;39(10):1370-6.

21. Olave M.C., Graham R.P. Mismatch repair deficiency: The what, how and why it is important. Genes Chromosomes Cancer 2022;61(6):314-21. DOI: 10.1002/gcc.23015

22. Avila M., Meric-Bernstam F. Next-generation sequencing for the general cancer patient. Clin Adv Hematol Oncol 2019;17(8):447-54.

23. Cho K.R., Cooper K., Croce S. et al. International Society of Gynecological Pathologists (ISGyP) endometrial cancer project: guidelines from the special techniques and ancillary studies group. Int J Gynecol Pathol 2019;38(Suppl 1):S114-S122.

24. Duraturo F., Liccardo R., De Rosa M., Izzo P. Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges. Oncol Lett 2019;17(3):3048-54. DOI: 10.3892/ol.2019.9945

25. Favier A., Varinot J., Uzan C. et al. The role of immunohistochemistry markers in endometrial cancer with mismatch repair deficiency: a systematic review. Cancers (Basel) 2022;14(15):3783. DOI: 10.3390/cancers14153783

26. Snowsill T.M., Ryan N.A.J., Crosbie E.J. et al. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS One 2019;14:e0221419. DOI: 10.1371/journal.pone.0221419

27. Daniels M.S., Urbauer D.L., Zangeneh A. et al. Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist. Gynecol Oncol 2013;131:619-23.

28. Oaknin A., Bosse T.J., Creutzberg C.L. et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33(9):860-77. DOI: 10.1016/j.annonc.2022.05.009

29. NCCN Guidelines Version 1.2022 Endometrial Carcinoma. Available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.

30. Casey L., Singh N. POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting. Int J Gynecol Pathol 2021;40(1):5-16.